AstraZeneca are taking a keen interest in cell therapy for cardiovascular disease. Here the Global Head of Research and Early Clinical Development at AstraZeneca is talking about MESO’s dream trial:
“There are also mesenchymal stem cells-based approaches in the clinic today and some rather large Phase 3 trials are being finalized this year. It will be interesting to see the outcome of these!”
Phase 3 DREAM HF-1 read-out, page-272
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |